Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2026
Event: Filing of a new automatic shelf registration statement (Form S-3ASR) to replace an expiring statement and updating the prospectus supplement for an At-The-Market (ATM) equity offering program.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The only financial data provided relates to the equity offering program:
- Remaining ATM Capacity: Up to $156.6 million (specifically $156,552,996.81) available for sale of common stock.
- Historical ATM Proceeds: $193,447,003.19 in aggregate gross sales price previously raised under the Sales Agreement with Jefferies LLC.
- Total Original Capacity: Approximately $350 million (sum of historical proceeds and remaining capacity).
Material Changes
The primary material change is the administrative replacement of the company's shelf registration statement:
- Registration Update: The Prior Registration Statement (No. 333-272936), filed on June 26, 2023, was deemed terminated as of May 5, 2026, upon the effectiveness of the New Registration Statement (No. 333-295560).
- Continuity: The new filing ensures the continuation of the Open Market Sales Agreement with Jefferies LLC, allowing the company to continue selling shares up to the remaining $156.6 million limit.
Guidance, Outlook, and Risks
Management Commentary: The filing is a routine regulatory update to maintain the ability to raise capital via the ATM program. No specific operational guidance or strategic outlook is provided in this document.
Risks and Contingencies: The filing includes a standard disclaimer that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration or qualification. The validity of the shares to be offered is supported by an opinion from Latham & Watkins LLP.
Investor Verification Checklist
- Verify the current market price of IDEAYA Biosciences common stock (IDYA) to assess the potential dilution impact of the remaining $156.6 million ATM capacity.
- Review the latest 10-Q or 10-K filings to understand the company's current cash position and burn rate, as this filing does not provide liquidity data.
- Confirm the terms of the Sales Agreement with Jefferies LLC to understand any commission fees or price restrictions associated with future sales.
- Monitor future 8-K filings for actual sales executed under the new registration statement.